These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
584 related articles for article (PubMed ID: 26422288)
21. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment. Chirico V; Rigoli L; Lacquaniti A; Salpietro V; Piraino B; Amorini M; Salpietro C; Arrigo T Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112 [TBL] [Abstract][Full Text] [Related]
22. Role of non-invasive assessment in prediction of preclinical cardiac affection in multi-transfused thalassaemia major patients. Said Othman KM; Elshazly SA; Heiba NM Hematology; 2014 Oct; 19(7):380-7. PubMed ID: 24225039 [TBL] [Abstract][Full Text] [Related]
23. Correlation of hepcidin level with insulin resistance and endocrine glands function in major thalassemia. Al-Hakeim HK; Al-Khakani MM; Al-Kindi MA Adv Clin Exp Med; 2015; 24(1):69-78. PubMed ID: 25923089 [TBL] [Abstract][Full Text] [Related]
24. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major. Waheed N; Ali S; Butt MA J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931 [TBL] [Abstract][Full Text] [Related]
25. Pulmonary Function in Children With Transfusion-Dependent Thalassemia and Its Correlation With Iron Overload. Baruah A; Bhattacharjee J Indian Pediatr; 2022 Jun; 59(6):455-458. PubMed ID: 35481484 [TBL] [Abstract][Full Text] [Related]
26. Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy. Karakukcu C; Karakukcu M; Unal E; Patiroglu T; Ozdemir MA; Torun YA; Tang PH Hemoglobin; 2012; 36(3):219-29. PubMed ID: 22483337 [TBL] [Abstract][Full Text] [Related]
27. Effect of using bedside leukocyte filter on pulmonary functions in patients with thalassemia major. Hamed Ael S; Ragab IA; Kamel TB; Abd-El-Gawad AO Pediatr Hematol Oncol; 2013 Nov; 30(8):761-7. PubMed ID: 24087980 [TBL] [Abstract][Full Text] [Related]
28. Cardiovascular effects of splenomegaly and splenectomy in beta-thalassemia. Aessopos A; Farmakis D; Deftereos S; Tsironi M; Polonifi A; Moyssakis I; Diamanti-Kandaraki E; Papalambros E Ann Hematol; 2005 Jun; 84(6):353-7. PubMed ID: 15711802 [TBL] [Abstract][Full Text] [Related]
29. Lungs in thalassaemia major patients receiving regular transfusion. Tai DY; Wang YT; Lou J; Wang WY; Mak KH; Cheng HK Eur Respir J; 1996 Jul; 9(7):1389-94. PubMed ID: 8836648 [TBL] [Abstract][Full Text] [Related]
30. Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients. Akrawinthawong K; Chaowalit N; Chatuparisuth T; Siritanaratkul N Hematology; 2011 Mar; 16(2):113-22. PubMed ID: 21418744 [TBL] [Abstract][Full Text] [Related]
31. Serum Hepcidin as a Diagnostic Marker of Severe Iron Overload in Beta-thalassemia Major. Kaddah AM; Abdel-Salam A; Farhan MS; Ragab R Indian J Pediatr; 2017 Oct; 84(10):745-750. PubMed ID: 28600663 [TBL] [Abstract][Full Text] [Related]
32. Pulmonary function abnormalities in thalassemia major and the role of iron overload. Factor JM; Pottipati SR; Rappoport I; Rosner IK; Lesser ML; Giardina PJ Am J Respir Crit Care Med; 1994 Jun; 149(6):1570-4. PubMed ID: 8004315 [TBL] [Abstract][Full Text] [Related]
33. Pulmonary function tests in children with beta-thalassemia major. Abu-Ekteish FM; Al-Rimawi HS; Al-Ali MK; Shehabi IM Chron Respir Dis; 2007; 4(1):19-22. PubMed ID: 17416149 [TBL] [Abstract][Full Text] [Related]
34. Relation of ferritin levels to pulmonary function in patients with thalassemia major and the acute effects of transfusion. Kanj N; Shamseddine A; Gharzeddine W; Kanj M; Nasr TA; Koussa S; Jibrail J; Taher A Eur J Haematol; 2000 Jun; 64(6):396-400. PubMed ID: 10901593 [TBL] [Abstract][Full Text] [Related]
35. [Program of hypertransfusion and chelation with desferrioxamine in 10 patients with thalassemia major]. Albo C; Cabrera J; Dios A; Castro M; Ares C; Constenla I; López D Sangre (Barc); 1995 Dec; 40(6):441-5. PubMed ID: 8850225 [TBL] [Abstract][Full Text] [Related]
36. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine. Moayedi B; Gharagozloo M; Esmaeil N; Maracy MR; Hoorfar H; Jalaeikar M Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124 [TBL] [Abstract][Full Text] [Related]
37. Comparison of diastolic function in children with transfusion dependent beta thalassemia major by tissue and conventional doppler imaging indices and its correlation with serum ferritin levels. Nanjegowda CK; Kamath SP; Kamath P; Shah TD; Kulkarni V; Lashkari HP; Baliga BS Turk J Pediatr; 2019; 61(2):250-256. PubMed ID: 31951335 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status. Limenta LM; Jirasomprasert T; Jittangprasert P; Wilairat P; Yamanont P; Chantharaksri U; Fucharoen S; Morales NP Clin Pharmacokinet; 2011 Jan; 50(1):41-50. PubMed ID: 21028920 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran. Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712 [TBL] [Abstract][Full Text] [Related]
40. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. Wu SF; Peng CT; Wu KH; Tsai CH Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]